Framework for managing relapsed or refractory acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study aims to collect data from patients diagnosed with relapsed or refractory acute myeloid leukemia (AML) across various clinical sites in Europe. The study seeks to monitor treatment outcomes and efficacy of new personalized therapies in real-world settings, addressing the significant challenges faced by patients with this hard-to-treat disease. By creating a master framework, the study will facilitate better understanding and management of R/R AML, contributing to improved patient care and treatment strategies. The initiative is part of the Horizon Europe Mission Cancer 2022 IMPACT-AML project, in collaboration with the European Reference Network on Rare Hematological Diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with AML diagnosis according to WHO2022 or ICC2022
* Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria
* Participant or his/her legal representative is willing and able to give informed consent for participation in the study

Exclusion Criteria:

* Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.

Where it's running

• University Hospital Aachen
  Aachen, Germany Recruiting
• University Hospital Greifswald
  Greifswald, Germany Recruiting
• University Hospital Halle
  Halle, Germany Recruiting
• University Hospital of Rostock
  Rostock, Germany Recruiting
• Policlinico Sant'Orsola-Malpighi
  Bologna, Bo, Italy Recruiting
• Ospedale "A. Perrino"
  Brindisi, Br, Italy Recruiting

Study contacts

• Study coordinator: Oriana Nanni
• Email: cc.ubsc@irst.emr.it
• Phone: +39 0543 739100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining cytokine-induced memory-like natural killer cells with atezolizumab for relapsed or refractory AML

  This trial will test whether giving cytokine-induced memory-like natural killer cells together with atezolizumab is safe and might help adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07011004

• Treatment with ARD103 CAR-T therapy for patients with relapsed or refractory AML or MDS

  This study is testing a new CAR-T therapy called ARD103 to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndrome.

  Recruiting at 3 sites Phase 1/2 ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06680752

• Investigating APL-4098 with Azacitidine for treating relapsed or refractory AML and high-risk MDS

  This study is testing a new treatment called APL-4098, alone and with azacitidine, to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia and high-risk myelodysplastic syndrome.

  Recruiting at 8 sites Phase 1 Apollo Therapeutics Ltd · Clayton, Victoria and 8 other locations · NCT06372717

• Using off-the-shelf CAR-NK cells to treat relapsed or refractory acute myeloid leukemia

  This study is testing a new treatment using specially modified immune cells to see if they can help people with relapsed or hard-to-treat acute myeloid leukemia feel better.

  Recruiting Early Phase 1 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06201247

• Using CAR-T cell therapy targeting Tim-3 and CD123 for treating relapsed acute myeloid leukemia

  This study is testing a new CAR-T cell therapy that targets specific markers in people aged 18-70 with relapsed acute myeloid leukemia to see if it can safely improve their treatment outcomes.

  Recruiting Phase 1/2 Xuzhou Medical University · Xuzhou, Jiangsu · NCT06125652

• Using CAR T cells to treat acute myeloid leukemia

  This study is testing a new treatment using specially modified CAR T cells to see if it can safely help adults and kids with tough cases of acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06017258

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.